It illustrates the interaction between endogenous immune cells (CD4+ T cells, CD8+ T cells, B cells and dendritic cells) and NY‐ESO‐1‐specific T‐cell receptor‐engineered cells (including natural killer cells, CD4+ T cells and CD8+ T cells) in targeting tumours. The gene discussed is CD4; the disease is neoplasm.